MCID: BRN126
MIFTS: 20

Brenner Tumor of Ovary

Categories: Rare diseases

Aliases & Classifications for Brenner Tumor of Ovary

MalaCards integrated aliases for Brenner Tumor of Ovary:

Name: Brenner Tumor of Ovary 53
Ovarian Brenner Tumor 53
Brenner Tumor 73

Classifications:



Summaries for Brenner Tumor of Ovary

NIH Rare Diseases : 53 A Brenner tumor of the ovary is a small, firm, smooth and solid growth (tumor) on the ovary.  Brenner tumors of the ovary usually do not cause symptoms.  Approximately 2% of all ovarian tumors are Brenner tumors.  There are three forms of this tumor: benign, proliferative (low chance of spreading beyond the original location of the tumor), and malignant.  The current preferred term for benign Brenner tumors of the ovary is transitional cell tumors.  These tumors usually occur in women ages 40 to 60 years.  Treatment usually consists of surgery to remove the tumor.  If a Brenner tumor has not spread into surrounding tissues or to more distant parts of the body, there is a good-to-excellent prognosis.

MalaCards based summary : Brenner Tumor of Ovary, also known as ovarian brenner tumor, is related to ovarian brenner tumor and malignant ovarian brenner tumor. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and brain.

Related Diseases for Brenner Tumor of Ovary

Diseases related to Brenner Tumor of Ovary via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ovarian brenner tumor 12.4
2 malignant ovarian brenner tumor 12.3
3 transitional cell carcinoma 10.0
4 lymphedema, hereditary, ii 9.9
5 papilloma 9.9
6 sarcoma 9.9
7 squamous cell carcinoma 9.9
8 endometrial stromal sarcoma 9.9
9 leiomyomatosis 9.9
10 diffuse peritoneal leiomyomatosis 9.9

Graphical network of the top 20 diseases related to Brenner Tumor of Ovary:



Diseases related to Brenner Tumor of Ovary

Symptoms & Phenotypes for Brenner Tumor of Ovary

Drugs & Therapeutics for Brenner Tumor of Ovary

Drugs for Brenner Tumor of Ovary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
4
Docetaxel Approved, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124
5
Bevacizumab Approved, Investigational Phase 3,Phase 1 216974-75-3
6
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
9
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
10 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
11 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
12 Antimitotic Agents Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
14 Alkylating Agents Phase 3,Phase 1
15 Mitogens Phase 3,Phase 1
16 Angiogenesis Inhibitors Phase 3,Phase 1
17 Angiogenesis Modulating Agents Phase 3,Phase 1
18 Endothelial Growth Factors Phase 3,Phase 1
19 Immunoglobulin G Phase 3,Phase 1
20 Antibodies Phase 3,Phase 1
21 Immunoglobulins Phase 3,Phase 1
22 Antibodies, Monoclonal Phase 3,Phase 1
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Alkylating Phase 3,Phase 1
25 Micronutrients Phase 3
26 Trace Elements Phase 3
27 Carotenoids Phase 3
28 taxane Phase 3
29 Anti-Infective Agents Phase 3,Phase 2
30 Antimetabolites Phase 3,Phase 2
31 Antiviral Agents Phase 3,Phase 2
32 Antimetabolites, Antineoplastic Phase 3,Phase 2
33 Analgesics Phase 3
34 Peripheral Nervous System Agents Phase 3,Not Applicable
35 Antirheumatic Agents Phase 3
36
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
37
Belinostat Approved, Investigational Phase 2 866323-14-0
38
Metformin Approved Phase 2 657-24-9 14219 4091
39
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
40
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
41
Doxil Approved June 1999 Phase 2,Phase 1 31703
42 Anti-Bacterial Agents Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 2,Phase 1
44
Erlotinib Hydrochloride Phase 2,Phase 1 183319-69-9 176871
45 Imatinib Mesylate Phase 2 220127-57-1 123596
46 Histone Deacetylase Inhibitors Phase 2
47 Protein Kinase Inhibitors Phase 2,Phase 1
48 Hypoglycemic Agents Phase 2
49
Lenograstim Approved, Investigational Phase 1 135968-09-1
50
Etoposide Approved Phase 1 33419-42-0 36462

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
6 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
7 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
8 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
9 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
10 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
11 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
12 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
13 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
14 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
15 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
16 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
17 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
18 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
19 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
20 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
21 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
22 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 metformin hydrochloride;placebo;Chemotherapy
23 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
24 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02101775 Phase 2 Adavosertib;Gemcitabine Hydrochloride
25 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
26 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
27 Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) Completed NCT00085358 Phase 1 carboplatin;paclitaxel;docetaxel
28 Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00079430 Phase 1 paclitaxel;carboplatin
29 Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer Completed NCT00002913 Phase 1 paclitaxel;cisplatin;topotecan hydrochloride
30 TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Completed NCT01294293 Phase 1 TLR8 Agonist VTX-2337;Pegylated Liposomal Doxorubicin Hydrochloride;Paclitaxel
31 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
32 Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Completed NCT00060359 Phase 1 Carboplatin;Paclitaxel Poliglumex
33 Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00814086 Phase 1 Paclitaxel;Cisplatin
34 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00006235 Phase 1 carboplatin;pegylated liposomal doxorubicin hydrochloride
35 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission Completed NCT00002977 Phase 1 melphalan;thiotepa
36 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003967 Phase 1 etoposide;topotecan hydrochloride
37 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer Completed NCT00005026 Phase 1 carboplatin;paclitaxel;topotecan hydrochloride
38 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
39 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
40 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00003385 Phase 1 carboplatin;paclitaxel;pegylated liposomal doxorubicin hydrochloride
41 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
42 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer Active, not recruiting NCT00408590 Phase 1
43 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Terminated NCT00003380 Phase 1 etoposide;pegylated liposomal doxorubicin hydrochloride
44 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
45 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
46 Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial Completed NCT00904514
47 Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Terminated NCT01275664 Not Applicable Aprepitant;Carboplatin;Cisplatin;Dexamethasone;Granisetron Transdermal Patch
48 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Brenner Tumor of Ovary

Genetic Tests for Brenner Tumor of Ovary

Anatomical Context for Brenner Tumor of Ovary

MalaCards organs/tissues related to Brenner Tumor of Ovary:

41
Ovary, Endothelial, Brain

Publications for Brenner Tumor of Ovary

Articles related to Brenner Tumor of Ovary:

# Title Authors Year
1
Malignant brenner tumor of ovary. ( 24757346 )
2014
2
Brenner tumor of ovary: An incidental finding. ( 21897739 )
2011
3
Proliferative and malignant Brenner tumors of ovary. Report of two cases, one with Meigs' Syndrome, review of literature, and ultrastructural comparisons. ( 955513 )
1976
4
Brenner tumor of ovary(?) (Urinary-tract-type papilloma). ( 13090149 )
1953
5
Brenner tumor of ovary; two cases associated with postmenopausal endometrial changes. ( 20241501 )
1947

Variations for Brenner Tumor of Ovary

Expression for Brenner Tumor of Ovary

Search GEO for disease gene expression data for Brenner Tumor of Ovary.

Pathways for Brenner Tumor of Ovary

GO Terms for Brenner Tumor of Ovary

Sources for Brenner Tumor of Ovary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....